Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 13/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CCKAR | P32238 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6176935 | 0.97 | CCKBR (0.46) | CCKBRCYP3A4MAPTTSHRPOLB | |
| SCHEMBL6179284 | 0.95 | CCKBR (0.51) | CCKBRCYP3A4MAPTTSHRCCKAR | |
| SCHEMBL6195641 | 0.91 | CCKBR (0.46) | CCKBRCYP3A4MAPTTSHRPOLB | |
| SCHEMBL6176419 | 0.91 | CCKBR (0.45) | CCKBRCYP3A4MAPTTSHRPOLB | |
| SCHEMBL6176367 | 0.91 | CCKBR (0.45) | CCKBRCYP3A4MAPTTSHRPOLB | |
| SCHEMBL6180171 | 0.91 | CCKBR (0.45) | CCKBRCYP3A4MAPTTSHRPOLB | |
| SCHEMBL6177496 | 0.91 | CCKBR (0.48) | CCKBRCYP3A4MAPTTSHRPOLB | |
| SCHEMBL6177002 | 0.90 | CCKBR (0.47) | CCKBRCYP3A4MAPTTSHRPOLB | |
| SCHEMBL7962872 | 0.90 | CCKBR (0.40) | CCKBRCYP3A4MAPTTSHRPOLB | |
| SCHEMBL6177719 | 0.89 | CCKBR (0.51) | CCKBRCYP3A4MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6239131-B1 | WHICH HAVE GASTRIN AND/OR CCK-B (CHOLECYSTOKININ-B) RECEPTOR ANTAGONISM, USEFUL AS REMEDIES FOR GASTRIC ULCER AND GASTROINTESTINAL MOVEMENT DISORDER. | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2001-05-29 | — | — | US | disclosed |